September 11, 2026 FDA Approves Isembyld as First Muscle-Targeted Treatment for Spinal Muscular Atrophy
June 19, 2026 Federal Officials Recalculate Medicare Advantage Star Ratings Amid Industry-Led Lawsuits
June 15, 2026 FDA Approves Teplizumab for Children With Stage 3 Type 1 Diabetes – Despite Delays & Controversy